Plus Therapeutics, Inc.
PSTV
$0.7691
-$0.075-8.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.54% | 17.42% | -31.01% | 231.42% | 769.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.54% | 17.42% | -31.01% | 231.42% | 769.54% |
| Cost of Revenue | -21.76% | 14.64% | 95.28% | -7.38% | 30.68% |
| Gross Profit | 47.74% | -11.89% | -444.24% | 56.16% | 25.47% |
| SG&A Expenses | 31.51% | 19.97% | 14.50% | -1.43% | -33.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.73% | 17.01% | 48.80% | -4.82% | -9.65% |
| Operating Income | -1.09% | -16.86% | -148.12% | 30.14% | 30.76% |
| Income Before Tax | -2.44% | 10.72% | -98.38% | 32.13% | 32.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.44% | 10.72% | -98.38% | 32.13% | 32.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.44% | 10.72% | -98.38% | 32.13% | 32.66% |
| EBIT | -1.09% | -16.86% | -148.12% | 30.14% | 30.76% |
| EBITDA | 0.16% | -16.43% | -165.19% | 31.11% | 31.52% |
| EPS Basic | 41.40% | 63.35% | 23.43% | 63.57% | 66.42% |
| Normalized Basic EPS | 41.39% | 63.34% | 23.41% | 63.57% | 66.42% |
| EPS Diluted | 41.40% | 63.00% | -20.32% | 63.57% | 66.42% |
| Normalized Diluted EPS | 41.39% | 63.34% | 53.67% | 63.57% | 66.42% |
| Average Basic Shares Outstanding | 74.81% | 143.56% | 159.06% | 86.28% | 100.53% |
| Average Diluted Shares Outstanding | 74.81% | 143.56% | 328.11% | 86.28% | 100.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |